This Market Spotlight report covers the Opioid-Induced Constipation market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.
- The approved drugs in the OIC space predominantly target opioid receptors, with the exception of Amitiza, a type-2 chloride channel activator. All of the marketed drugs are administered via the oral route, with one product also available in subcutaneous formulation.
- The majority of industry-sponsored drugs in active clinical development for OIC are in Phase II, with only one drug in Phase III. Therapies in mid-to-late-stage development for OIC focus on targets such as opioid receptors and guanylyl cyclase c receptor. All of the pipeline drugs are administered via the oral route.
- A Committee for Medicinal Products for Human Use (CHMP) opinion for Symproic is the only high-impact upcoming event in the OIC space.
- There was only one licensing agreement involving OIC drugs during 2013-17.
Key Topics Covered:
Management of OIC with laxatives
Management of OIC with opioid antagonists
Management of OIC with Amitiza, a secretagogue chloride channel activator
Recent Prevalence Studies
KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
Purdue Highlights Convenience Of New Opioid-Induced Constipation Drug Symproic
Valeant's Oral Relistor Poised To Face-Off Against AstraZeneca's Movantik
LICENSING AND ASSET ACQUISITION DEALS
For more information about this report visit https://www.researchandmarkets.com/research/zkdvt7/market_spotlight?w=4